Drugs / VVD-159642
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06804824 | Feb 2025 → Aug 2027 expected | cancer | Vividion Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VVD-159642 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06804824 ↗ |
| Action | Inhibit | “RAS-PI3Kα inhibitor” NCT06804824 ↗ |
| Route | Oral | “Oral capsules” NCT06804824 ↗ |